摘要
目的:观察干扰素对HBeAg阳性慢性乙型肝炎患者的临床疗效。方法:以干扰素α-1b治疗50例HBeAg阳性慢性乙型肝炎患者,5MU/次,肌注,疗程24周。治疗前后定期检测血清HBV DNA和PBMV HBV DNA含量、血清HBV标志物、肝功能指标,观察其水平变化和应答率情况。结果:单用IFN-α-1b治疗50例HBeAg(+)的慢性乙肝患者,经过半年疗程之后,其生化应答率达到42%,血清免疫学应签率达到48%(部分应答3%,完全应答10%),病毒学应答率达到40%(部分应答28%,完全应答12%);生化学、血清免疫学和病毒学的持续应答率也分别达到50%、44%和34%。结论:IFN-α-1b对HBeAg阳性慢性乙型肝炎患者有较好的临床疗效,并对PBMC内的HBV DNA有较好的抑制作用。但尚需通过联合用药以提高其总体疗效。
Objective：To observe the clinical curative effect of interferon α-1b in chronic hepatitis B with HBeAg positive.Methods：Interferon α-1b was used to treat 50 cases of chronic hepatitis B with HBeAg positive.The dose was 5MU IM per day for one week,then 5MU IM every tow days for 23 weeks.Sera HBV-DNA,prripheral blood mononuclear cells HBV-DNA,sera HBV markers and liver function were detected pre-and post-treatment periodical to estimate the curative effect of interferon α-1b.Results：When treated by interferon α-1b for 24 weeks in 50cases,the biochemical response rate was 42%,the sera insera immunological response rate was 48%（partial response rate was 38%,complete response rate was 10%）,the virological rate was 40%（partial response rate was 38%,complete response rate was 10%）.The persistent response rates of biochemical,sera immunological and verological were 50%,44% and 34% respectively.The titer of PBMC HBV-DNA was reduced following the treatment of interferon α-1b,and kept in a significant lower level after 24 weeks of ending therapy than that of pretreatment.Conclusions：Interferon α-1b can obtain a advantageous clinical curative effect in chronic hepatitis B with HBeAg positive cases and can restrain intracellular HBV-DNA of PBMC well.But the effect still need to improve by combine protocol.
出处
《华西医学》
CAS
2008年第3期537-538,共2页
West China Medical Journal
